Evaxion A/S (NASDAQ:EVAX – Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect Evaxion A/S to post earnings of ($0.01) per share and revenue of $0.30 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 19, 2026 at 8:30 AM ET.
Evaxion A/S Stock Up 1.1%
Evaxion A/S stock opened at $2.77 on Tuesday. Evaxion A/S has a twelve month low of $2.65 and a twelve month high of $6.92. The stock’s fifty day simple moving average is $3.12 and its 200-day simple moving average is $3.42. The company has a current ratio of 5.06, a quick ratio of 5.06 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $24.99 million, a P/E ratio of -2.29 and a beta of 0.60.
Analysts Set New Price Targets
A number of research firms recently issued reports on EVAX. Wall Street Zen upgraded Evaxion A/S to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.
About Evaxion A/S
Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.
Read More
- Five stocks we like better than Evaxion A/S
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
